Cytokine News and Research

RSS

African Americans more likely to carry genetic variants known to stimulate inflammatory response

Specific variants in genes that encode proteins regulating inflammation may hold a key to explaining a host of disease processes known to cause increased risk of illness and death among African Americans, according to a study from the University of Pittsburgh's Graduate School of Public Health (GSPH).

1 Dec 2004

New research may lead to treatments for atherosclerosis

Scientists are one step closer to deciphering the molecular signaling process controlling innate immunity with the discovery that a molecule called IRAK1 regulates the expression of the anti-inflammatory cytokine IL-10. Because atherosclerosis patients often have elevated IL-10 levels, IRAK1 may be a viable target for developing therapeutics for atherosclerosis.

29 Nov 2004

Scientists have determined the crystal structure of a protein kinase C (PKC) isozyme

This structure should prove extremely useful in the rational design of small molecule inhibitors of PKCÈ, which has been implicated in T-cell mediated disease processes including inflammation and autoimmunity.

19 Nov 2004

Shp2 protein plays a critical role in obesity

A team of researchers led by The Burnham Institute's Gen-Sheng Feng, Ph.D. has discovered that a protein called Shp2 plays a critical role in obesity.

11 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

The first test in humans of a bioartificial kidney

The first test in humans of a bioartificial kidney offers hope of the device's potential to save the lives of people with acute renal failure, researchers at the University of Michigan Health System report.

4 Nov 2004

Psoriasis trial enters final stage

Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.

4 Nov 2004

Researchers have uncovered a specific signaling mechanism that contributes to the development of colorectal cancer

The discovery furthers the understanding of mechanisms that contribute to disease progression and provides new avenues for development of therapies for colorectal cancer.

21 Oct 2004

Signaling pathway could be a valuable target for future drug therapies against systemic lupus erythematosus

Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in “Nature Immunology.”

11 Oct 2004

Interleukin-6 has potential as a therapeutic drug in treating metabolic disorders such as obesity, type 2 diabetes and atherosclerosis

For the most of the past century, researchers have searched for a muscle-contraction-induced factor, which mediates some of the exercise effects in other tissues and organs such as the liver and adipose tissue.

5 Oct 2004

Moderate exercise in mice after they were infected with influenza protects them from dying

University of Illinois researchers report that four consecutive days of moderate exercise in mice after they were infected with influenza protects them from dying, compared with mice that didn’t exercise.

5 Oct 2004

A new non-invasive test for kidney disease

A new non-invasive test for kidney disease, developed by clinicians at Hammersmith Hospitals NHS Trust and Imperial College London, is providing a simple, safe, cheap and reliable method of detecting kidney disease.

13 Sep 2004

New treatment for T-cell acute lymphoblastic leukaemia

IL-7, a hormone-like protein involved in cell-cell interaction, has been associated with increased survival and expansion of T-cell acute lymphoblastic leukaemia (T-ALL).

9 Sep 2004

Smart drug that targets cancer cells in the brain following removal of a tumor

The use of a "smart" drug that targets cancer cells in the brain following removal of a tumor may provide treatment that can extend the survival of people with the most common form of primary malignant brain tumor, glioblastoma multiforme (GBM).

3 Aug 2004

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

Misfiring proteins linked to sick feeling of type 2 diabetics

After a series of studies in the laboratory of Dr. Gregory Freund, a clearer picture is emerging: A disruption of signaling proteins in the immune system may be responsible for the inflammation that makes someone with type 2 diabetes feel sick and increases the risk of serious complications.

29 Jul 2004

Molecular pathway in the brain may explain why some patients suffering from inflammatory diseases develop depression

Feeling sick can be "all in the head" for people with inflammatory disorders or for those receiving immunotherapy, say Robert Dantzer and Keith Kelley, professors in the department of animal sciences at the University of Illinois at Urbana-Champaign.

29 Jul 2004

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

At the XVth International AIDS Conference in Bangkok, Thailand, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases and chief of the NIAID Laboratory of Immunoregulation (LIR), will present his laboratory’s latest findings on how aberrant immune activation underlies HIV pathogenesis.

15 Jul 2004

Immunotherapeutic strategy allowing patients to use their own immune system to fight their cancer

Scientists affiliated with the Harvard University Medical School have devised ways of bolstering patients' immune response against kidney and breast cancer.